STOCK TITAN

International Flavors & Fragrances Inc. - IFF STOCK NEWS

Welcome to our dedicated page for International Flavors & Fragrances news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors & Fragrances stock.

International Flavors & Fragrances Inc. (IFF) is a leading innovator in creating sensorial experiences that drive the world of flavors and fragrances. Headquartered in New York, the company partners with customers globally to develop unique products for the food, beverage, health, personal care, and household goods industries. With a strong commitment to discovery and innovation, IFF continuously explores new possibilities in both fine fragrances and beauty, as well as in beloved foods and beverages.

IFF's core businesses include the Nourish segment, which accounts for nearly half of its revenue. This segment specializes in producing flavors, texturants, and plant-based proteins, providing essential ingredients that enhance the appeal and functionality of food products. Additionally, the Health & Biosciences division, generating roughly one-fourth of the company's revenue, is renowned for its expertise in probiotics and enzymes, making significant contributions to health and wellness solutions.

The company leverages its global team of 7,300 professionals along with leading consumer insights, research and development, and creative expertise to deliver differentiated products. Their proprietary formulations and custom solutions are a testament to their innovative approach and customer-centric focus.

IFF has recently made remarkable advancements in excipient technology, presenting its comprehensive range at global events such as CPhI Japan 2024 and Vitafoods Europe 2024. These showcases highlight the company's commitment to driving pharmaceutical innovation, with notable products like METHOCEL™, ETHOCEL™, and POLYOX™ under its new controlled release platform, 'Timing is Everything'. This new platform emphasizes the importance of controlled release in pharmaceutical therapies, aiming to improve patient compliance and treatment efficacy.

IFF continues to expand its innovative offerings and partnerships, demonstrating a significant impact across various industries. The company's dedication to sustainability and precision in science and creativity positions it as a key player in transforming everyday experiences and contributing to a better world.

For more detailed information about their latest projects and developments, visit their official website at iff.com.

Rhea-AI Summary

IFF (NYSE:IFF) will release its second quarter 2024 earnings results on August 6, 2024, after the market closes.

A live webcast to discuss the results and future outlook will be hosted by the management team on August 7, 2024, at 9:00 a.m. ET.

Investors can access the live webcast and slide presentation via the company's website, with a recorded version available for replay.

IFF specializes in creating solutions for the food, beverage, health, biosciences, and scent industries, blending science and creativity.

For further information, media and investor relations contacts are provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary

IFF has received EU-wide regulatory approval for two new feed solutions for poultry: Axtra® XAP and Syncra® AVI. These products, developed by Danisco Animal Nutrition & Health, aim to improve poultry performance and reduce feed costs.

Axtra® XAP is a blend of xylanase, amylase, and protease enzymes, which enhances nutrient absorption and allows for flexible dietary formulations. Syncra® AVI combines enzymes and probiotics to optimize gut health and overall productivity. These solutions are also available in North America, South Africa, and Asia Pacific.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
Rhea-AI Summary

IFF (NYSE: IFF) has appointed Margarita Paláu-Hernández to its Board of Directors, effective June 3, 2024. This appointment aligns with IFF's cooperation agreement with Icahn Capital LP. The Board will now consist of 11 members, 10 of whom are independent. Roger Ferguson, lead director of IFF, emphasized Paláu-Hernández's legal expertise and consumer insights as critical assets for IFF's growth and transformation plan. Carl Icahn, CEO of Icahn Capital, also expressed confidence in Paláu-Hernández's ability to contribute to IFF's strategic advancements and shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
management
Rhea-AI Summary

IFF has released its 2023 Do More Good Report, detailing its progress in environmental, social, governance, and sustainability (ESG+) strategies. Key accomplishments include helping avoid 24.6 million tonnes of CO2e emissions, achieving ESG leadership recognition, and reducing Scope 1 and 2 GHG emissions by 21% from 2021 levels. The report highlights the company's four strategic pillars: Sustainable Solutions, Climate & Planetary Health, Equity & Wellbeing, and Transparency & Accountability. Additional achievements include completing nine human rights impact assessments, obtaining zero waste to landfill verification for ten new facilities, and achieving no statistically relevant gender pay gap in 27 countries. IFF continues to support sustainable innovation, emphasizing its role in driving industry-wide change.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Summary

IFF (NYSE: IFF), a leader in food, beverage, health, and personal care, will unveil groundbreaking alginate biopolymer technologies at two major biomedical conferences. At the World Biomaterials Congress (WBC) in Daegu, South Korea, from May 26-31, IFF will present a self-gelling alginate hydrogel system that offers a minimally invasive way to deliver therapeutics. This system combines calcium alginate suspension with soluble sodium alginate, which self-gels within minutes of injection.

In June, IFF will present at the TERMIS World Congress in Seattle, showcasing macroporous alginate foam scaffolds for 3D cell culture. These innovations provide non-animal-based cell culture environments, supporting tissue engineering and therapeutic screening. IFF's NovaMatrix® portfolio of ultrapure alginate biopolymers is poised to revolutionize regenerative medicine and 3D cell culture applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

On May 15, 2024, IFF (NYSE: IFF), a global leader in various consumer markets, announced the launch of a new controlled release platform. This platform includes their established products METHOCEL™, ETHOCEL™, and POLYOX™. Marketed under the slogan, 'Timing is Everything,' this initiative aims to enhance pharmaceutical therapies by improving the controlled release of active ingredients, thereby boosting patient compliance. The platform also offers educational resources and access to subject matter experts. Jason Hunt, IFF's global strategic marketing manager, highlighted the company's commitment to supporting pharmaceutical formulators and accelerating therapeutic innovations to the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
Rhea-AI Summary

IFF announced that Glenn Richter, the Chief Financial and Business Transformation Officer, will retire on Dec. 31, 2024, after three years with the company. The succession process has started to find a new CFO. Richter's contributions in improving the balance sheet and driving financial success were highlighted by Erik Fyrwald, IFF CEO.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
none
-
News
Rhea-AI Summary

IFF reported financial results for the first quarter of 2024, showing a decrease in net sales but an improvement in adjusted operating EBITDA. The company's CEO mentioned a good start to the year with volume growth and productivity gains, along with important strategic steps taken to optimize the portfolio. Despite uncertainty, the company expects results to trend towards the higher end of its guidance ranges for the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
-
Rhea-AI Summary

IFF will showcase its comprehensive clean-label portfolio at Vitafoods Europe 2024, focusing on plant-based solutions for supplements and OTC drugs. The company aims to address rising demand for clean-label products through innovative solutions. IFF Health will also highlight offerings for women's health and skin health, emphasizing the Healthy Aging campaign.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
none
Rhea-AI Summary

IFF (NYSE: IFF) announced a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2024 to shareholders of record as of June 21, 2024. The company is a leader in food, beverage, scent, health, and biosciences, providing essential solutions for a better world through science and creativity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
dividends earnings

FAQ

What does International Flavors & Fragrances Inc. (IFF) do?

IFF is a global leader in creating flavors and fragrances for the food, beverage, health, personal care, and household goods industries.

What are the core business segments of IFF?

IFF's core business segments include Nourish, which produces flavors and plant-based proteins, and Health & Biosciences, known for probiotics and enzymes.

Where is IFF headquartered?

IFF is headquartered in New York, USA.

How many employees does IFF have?

IFF employs approximately 7,300 professionals globally.

What are some recent innovations by IFF?

IFF has recently launched a new controlled release platform named 'Timing is Everything' and showcased advanced excipient technologies at global events.

What is the significance of the 'Timing is Everything' platform?

The 'Timing is Everything' platform emphasizes the importance of controlled release in pharmaceuticals, improving patient compliance and treatment efficacy.

How does IFF support the food industry?

The Nourish segment of IFF provides flavors, texturants, and plant-based proteins that enhance the appeal and functionality of food products.

What role does IFF play in the health sector?

IFF's Health & Biosciences division is a global leader in probiotics and enzymes, contributing significantly to health and wellness solutions.

Where can I find more information about IFF's products and services?

For more information about IFF’s products and services, visit their official website at http://www.iff.com.

What is IFF's approach to innovation?

IFF embraces a passion for discovery, continuously exploring new possibilities to co-create unique scents and tastes in various industries.

International Flavors & Fragrances Inc.

NYSE:IFF

IFF Rankings

IFF Stock Data

25.06B
255.35M
0.05%
95.71%
1.47%
All Other Basic Organic Chemical Manufacturing
Manufacturing
Link
United States of America
NEW YORK